scispace - formally typeset
C

Cornelis P. Vlaar

Researcher at University of Puerto Rico, Medical Sciences Campus

Publications -  22
Citations -  455

Cornelis P. Vlaar is an academic researcher from University of Puerto Rico, Medical Sciences Campus. The author has contributed to research in topics: Metastasis & Cancer. The author has an hindex of 6, co-authored 16 publications receiving 376 citations. Previous affiliations of Cornelis P. Vlaar include University of Puerto Rico.

Papers
More filters
Book ChapterDOI

Development of EHop-016: A Small Molecule Inhibitor of Rac

TL;DR: EHop-016 is identified as a compound that blocks the interaction of Rac with the GEF Vav in metastatic human breast cancer cells with an IC50 of ~1μM and inhibits the activation of the Rac downstream effector p21-activated kinase, extension of motile actin-based structures, and cell migration.
Journal ArticleDOI

Pharmacokinetics of the Rac/Cdc42 Inhibitor MBQ-167 in Mice by Supercritical Fluid Chromatography–Tandem Mass Spectrometry

TL;DR: The pharmacokinetics and tissue distribution of MBQ-167 following intraperitoneal and oral single-dose administrations are reported and supports further preclinical evaluation of this drug as a potential anticancer therapeutic.
Journal ArticleDOI

Solubility Measurements and Correlation of MBQ-167 in Neat and Binary Solvent Mixtures

TL;DR: MBQ-167 as discussed by the authors is a dual inhibitor of Rac and Cdc42, small GTPases that are involved in cytoskeletal organization, cell cycle progression, and cell migration.
Journal ArticleDOI

Synthesis of 1,4-Dihydro-benzo[d][1,3]oxazin-2-ones from Phthalides via an Aminolysis-Hofmann Rearrangement Protocol.

TL;DR: In this paper, a simple two-step procedure for the conversion of readily available phthalides to the corresponding benzoxazinones was developed, starting with ring-opening aminolysis to form a primary 2-hydroxymethylbenzamide, followed by reaction with bis(trifluoroacetoxy)iodobenzene (BTI) conveniently, provided a variety of 4-substituted benzoxinones.
Journal ArticleDOI

Out-smarting smart drug modafinil through flow chemistry

TL;DR: Modafinil is an anti-narcoleptic drug used to treat excessive daytime sleepiness associated with sleep apnea and shift-work disorder and it is unique in its lack of significant side-effects or addiction-inducing properties.